ES2050070B1 - Procedimiento para la preparacion de una composicion destinada a la liberacion prolongada y controlada de una substancia peptidica. - Google Patents

Procedimiento para la preparacion de una composicion destinada a la liberacion prolongada y controlada de una substancia peptidica.

Info

Publication number
ES2050070B1
ES2050070B1 ES09201523A ES9201523A ES2050070B1 ES 2050070 B1 ES2050070 B1 ES 2050070B1 ES 09201523 A ES09201523 A ES 09201523A ES 9201523 A ES9201523 A ES 9201523A ES 2050070 B1 ES2050070 B1 ES 2050070B1
Authority
ES
Spain
Prior art keywords
preparation
prolonged
procedure
controlled release
composition intended
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES09201523A
Other languages
English (en)
Spanish (es)
Other versions
ES2050070A1 (es
Inventor
Piero Orsolini
Frederic Heimgartner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asta Medica GmbH
Original Assignee
Asta Medica GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica GmbH filed Critical Asta Medica GmbH
Publication of ES2050070A1 publication Critical patent/ES2050070A1/es
Application granted granted Critical
Publication of ES2050070B1 publication Critical patent/ES2050070B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES09201523A 1991-07-22 1992-07-21 Procedimiento para la preparacion de una composicion destinada a la liberacion prolongada y controlada de una substancia peptidica. Expired - Fee Related ES2050070B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH2178/91A CH683149A5 (fr) 1991-07-22 1991-07-22 Procédé pour la préparation de microsphères en matériau polymère biodégradable.

Publications (2)

Publication Number Publication Date
ES2050070A1 ES2050070A1 (es) 1994-05-01
ES2050070B1 true ES2050070B1 (es) 1994-10-01

Family

ID=4227716

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09201523A Expired - Fee Related ES2050070B1 (es) 1991-07-22 1992-07-21 Procedimiento para la preparacion de una composicion destinada a la liberacion prolongada y controlada de una substancia peptidica.
ES9201522A Expired - Fee Related ES2037621B1 (es) 1991-07-22 1992-07-21 Procedimiento para la preparacion de microesferas de material polimero biodegradable.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES9201522A Expired - Fee Related ES2037621B1 (es) 1991-07-22 1992-07-21 Procedimiento para la preparacion de microesferas de material polimero biodegradable.

Country Status (40)

Country Link
US (2) US5445832A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP3600252B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR930702018A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1054543C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (2) AT403348B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU652844B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (2) BE1005697A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9205375A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (2) CA2074320C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (2) CH683149A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ287585B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (3) DE4223282A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK176219B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EE (1) EE03014B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2050070B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (2) FI105318B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (2) FR2679450B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (2) GB2257973B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (2) GR1001446B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP920229A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU218203B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (2) IE69967B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL102591A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (2) IT1259892B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (2) LU88150A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9204268A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (2) NL194576C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO304057B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ243643A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH31564A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL169387B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT100712B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2103994C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (2) SE512609C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI9200152B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK280612B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW260610B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA35569C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1993001802A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (2) ZA925485B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
EP0626170A3 (en) 1993-05-10 1996-03-27 Sandoz Ltd Stabilization of pharmacologically active compounds in delayed release agents.
DE4320201A1 (de) * 1993-06-18 1995-01-12 Asta Medica Ag Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation
US6087324A (en) * 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
DE4342092B4 (de) * 1993-12-09 2007-01-11 Zentaris Gmbh Langwirkende Injektionssuspension und Verfahren zur Herstellung
EP0835101B1 (en) 1995-06-27 2004-06-09 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
US5931809A (en) * 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
KR0162872B1 (ko) * 1996-04-01 1998-12-01 김은영 용매추출법을 이용한 생분해성 고분자 미립구의 개선된 제조방법 및 이를 이용한 국소염증 질환 치료용 미립구의 제조방법
US20020111603A1 (en) * 1996-12-02 2002-08-15 Societe De Conseils De Recherches Et D'application Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
WO1998032423A1 (en) * 1997-01-29 1998-07-30 Takeda Chemical Industries, Ltd. Sustained-release microspheres, their production and use
MY118835A (en) * 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
US6465015B1 (en) * 1998-02-24 2002-10-15 Arch Chemicals, Inc. Sonic method of enhancing chemical reactions to provide uniform, non-agglomerated particles
AU3108299A (en) * 1998-03-18 1999-10-11 University Technology Corporation Sustained-release composition including amorphous polymer
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
SE9801288D0 (sv) * 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
US6270700B1 (en) 1998-07-23 2001-08-07 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Encapsulation of water soluble peptides
EP1240896A3 (en) * 1998-07-23 2003-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Encapsulation of water soluble peptides
US20070009605A1 (en) * 1998-07-23 2007-01-11 Ignatious Francis X Encapsulation of water soluble peptides
DK1098660T3 (da) * 1998-07-23 2003-02-17 Sod Conseils Rech Applic Indkapsling af vandopløselige peptider
WO2000004916A1 (en) * 1998-07-23 2000-02-03 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Encapsulation of water soluble peptides
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
GB2344519B (en) * 1998-12-07 2004-05-19 Johnson & Johnson Medical Ltd Sterile therapeutic compositions
IT1304152B1 (it) * 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
US6682724B2 (en) 1999-02-23 2004-01-27 Arch Chemcials, Inc. Sonic method of enhancing chemical reactions to provide uniform, non-agglomerated particles
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
US6317623B1 (en) * 1999-03-12 2001-11-13 Medrad, Inc. Apparatus and method for controlling contrast enhanced imaging procedures
JP2002539172A (ja) 1999-03-17 2002-11-19 ノバルティス アクチエンゲゼルシャフト Ｔｇｆ−ベータを含む医薬組成物
EP1044683A1 (en) * 1999-04-15 2000-10-18 Debio Recherche Pharmaceutique S.A. One-step dispersion method for the microencapsulation of water soluble substances
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
ES2169980B1 (es) 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
US6309454B1 (en) 2000-05-12 2001-10-30 Johnson & Johnson Medical Limited Freeze-dried composite materials and processes for the production thereof
AU2002235253A1 (en) 2000-12-21 2002-07-01 Inhale Therapeutic Systems, Inc. Induced phase transition method for the production of microparticles containing hydrophilic active agents
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
EP1429749A2 (en) * 2001-09-26 2004-06-23 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
KR100885070B1 (ko) * 2002-05-08 2009-02-25 재단법인서울대학교산학협력재단 Ｐｌｇａ에 특이적으로 부착하는 올리고 펩타이드
US7601688B2 (en) 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
CA2509755A1 (en) * 2002-12-27 2004-07-22 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
DE602004007105T2 (de) 2003-01-28 2008-02-28 Microbia Inc., Cambridge Zusammensetzung zur behandlung von gastrointestinalen störungen
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN1938040A (zh) * 2003-03-05 2007-03-28 Pr药品有限公司 缩宫素控释制剂及其应用方法
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
JP5105578B2 (ja) 2003-11-05 2012-12-26 サーコード バイオサイエンス インコーポレイテッド 細胞接着のモジュレーター
CN105801686B (zh) * 2004-07-19 2020-04-07 比奥孔有限公司 胰岛素-低聚物共轭物、制剂及其用途
EP2594259A1 (en) 2004-08-04 2013-05-22 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
ES2255426B1 (es) 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
EP1838305A1 (en) * 2005-01-21 2007-10-03 Richard H. Matthews Radiosensitizer formulations comprising nitrohistidine derivatives
US20080095849A1 (en) * 2005-04-25 2008-04-24 Amgen Inc. Peptide sustained release compositions and uses thereof
SI1881823T1 (sl) 2005-05-17 2015-04-30 Sarcode Bioscience Inc. Sestavki in postopki za zdravljenje bolezni oäśesa
CA2608930A1 (en) * 2005-06-14 2006-12-28 Baxter International Inc. Pharmaceutical formulations for minimizing drug-drug interactions
EP1954245A2 (en) * 2005-11-15 2008-08-13 Baxter International Inc. Compositions of lipoxygenase inhibitors
KR20130024987A (ko) * 2005-12-22 2013-03-08 노파르티스 아게 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
EP1983917B1 (en) * 2006-01-27 2014-06-25 Spinal Ventures, LLC Low pressure delivery system for delivering a solid and liquid mixture into a target site for medical treatment
KR100722607B1 (ko) * 2006-05-11 2007-05-28 주식회사 펩트론 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
US7403325B2 (en) * 2006-05-19 2008-07-22 Xerox Corporation Electrophoretic display device
RU2326655C1 (ru) * 2006-11-09 2008-06-20 Федеральное государственное учреждение "48 Центральный научно-исследовательский институт Министерства обороны Российской Федерации" Способ инкапсулирования белоксодержащих веществ в микросферы из сополимера полилактид-полигликолид
US20080293695A1 (en) * 2007-05-22 2008-11-27 David William Bristol Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US8211905B1 (en) 2007-05-22 2012-07-03 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US7858663B1 (en) 2007-10-31 2010-12-28 Pisgah Laboratories, Inc. Physical and chemical properties of thyroid hormone organic acid addition salts
US10183001B1 (en) 2007-05-22 2019-01-22 Pisgah Laboratories, Inc. Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US9421266B2 (en) 2007-05-22 2016-08-23 Pisgah Laboratories, Inc. Safety of pseudoephedrine drug products
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8329720B1 (en) 2007-05-22 2012-12-11 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting abuse deterrent and anti-dose dumping properties
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
PT2500014T (pt) * 2007-06-06 2018-11-21 Debiopharm Int Sa Composição farmacêutica de libertação prolongada constituída por micropartículas
AU2008313248B2 (en) 2007-10-16 2012-04-26 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
CA3105972A1 (en) 2007-10-19 2009-04-30 Novartis Ag Compositions and methods for treatment of diabetic retinopathy
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
EP2276508A4 (en) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc ADMINISTRATION OF LFA-1 ANTAGONISTS TO THE GASTROINTESTINAL SYSTEM
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20100062057A1 (en) * 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
JP6176894B2 (ja) 2009-03-09 2017-08-09 プロノヴァ・バイオファーマ・ノルゲ・アーエス 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
ES2363965B1 (es) 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
ES2363964B1 (es) 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
US20130236551A1 (en) 2009-12-23 2013-09-12 Defiante Farmaceutica .S.A. Combination composition useful for treating cardiovascular diseases
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2835018C (en) 2011-05-04 2020-04-21 Balance Therapeutics, Inc. Pentylenetetrazole derivatives
WO2013072767A1 (en) 2011-11-18 2013-05-23 Pronova Biopharma Norge As Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
EP2833740B1 (en) 2012-04-04 2016-09-14 Pronova BioPharma Norge AS Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
US9585896B2 (en) 2012-04-04 2017-03-07 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin D for psoriasis, and methods and uses thereof
PT2851085T (pt) * 2012-05-14 2019-10-11 Teijin Pharma Ltd Composição proteica esterilizada por radiação
WO2014018748A1 (en) 2012-07-25 2014-01-30 Sarcode Bioscience Inc. Lfa-1 inhibitor and polymorph thereof
AU2014218599C1 (en) 2013-02-25 2018-09-06 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for use in colonic cleansing
CN105120842B (zh) 2013-02-28 2020-12-01 普罗诺瓦生物医药挪威公司 包含脂质化合物、甘油三酯和表面活性剂的组合物以及使用它们的方法
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
EP3054969B1 (en) 2013-10-10 2021-03-10 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
US10046058B2 (en) * 2014-12-02 2018-08-14 Rezolute, Inc. Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
US20180104201A1 (en) 2015-04-28 2018-04-19 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and or treating non alcoholic steatohepatitis
CA3009814A1 (en) 2016-01-11 2017-07-20 Synergy Pharmaceuticals, Inc. Formulations and methods for treating ulcerative colitis
US11052046B2 (en) 2017-09-26 2021-07-06 Nanomi B.V. Method for preparing micro-particles by double emulsion technique
MX2020005621A (es) 2017-12-06 2020-08-20 Basf As Derivados de acidos grasos para tratar la esteatohepatitis no alcoholica.

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2010115A1 (de) * 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
JPS523342B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1972-01-26 1977-01-27
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4341767A (en) * 1980-10-06 1982-07-27 Syntex Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
ATE61935T1 (de) * 1985-02-07 1991-04-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US4666704A (en) * 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
IL79134A (en) * 1985-07-29 1991-06-10 American Cyanamid Co Continuous release peptide implants for parenteral administration
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US5000886A (en) * 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH672887A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1987-10-14 1990-01-15 Debiopharm Sa
US5187150A (en) * 1987-10-14 1993-02-16 Debiopharm S.A. Polyester-based composition for the controlled release of polypeptide medicinal substances
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
EP0471036B2 (en) * 1989-05-04 2004-06-23 Southern Research Institute Encapsulation process
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
CH681425A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1990-11-14 1993-03-31 Debio Rech Pharma Sa
CH679207A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1989-07-28 1992-01-15 Debiopharm Sa
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.

Also Published As

Publication number Publication date
CA2074320C (en) 1999-04-06
ES2037621A1 (es) 1993-06-16
AT403348B (de) 1998-01-26
FI923320L (fi) 1993-01-23
FR2679450A1 (fr) 1993-01-29
ES2037621B1 (es) 1994-02-01
FI105318B (fi) 2000-07-31
IE922367A1 (en) 1993-01-27
FI106925B (fi) 2001-05-15
HUT64234A (en) 1993-12-28
PT100712A (pt) 1993-10-29
PH31564A (en) 1998-11-03
WO1993001802A1 (fr) 1993-02-04
UA35569C2 (uk) 2001-04-16
BE1005697A5 (fr) 1993-12-21
IE922366A1 (en) 1993-01-27
GB9215480D0 (en) 1992-09-02
ITBS920093A1 (it) 1994-01-21
LU88151A1 (fr) 1993-02-15
NL9201309A (nl) 1993-02-16
SK38293A3 (en) 1993-08-11
CN1070344A (zh) 1993-03-31
PL298504A1 (en) 1994-01-10
SE9202212D0 (sv) 1992-07-21
AU652844B2 (en) 1994-09-08
SE512609C2 (sv) 2000-04-10
SE9202213L (sv) 1993-01-23
GB2257973B (en) 1996-02-28
DK93892A (da) 1993-01-23
PL169387B1 (pl) 1996-07-31
LU88150A1 (fr) 1993-02-15
SE512670C2 (sv) 2000-04-17
CH683149A5 (fr) 1994-01-31
AU2043692A (en) 1993-01-28
IL102590A0 (en) 1993-01-14
GB9215479D0 (en) 1992-09-02
FI923321L (fi) 1993-01-23
NO304057B1 (no) 1998-10-19
NO922886D0 (no) 1992-07-21
JPH06172208A (ja) 1994-06-21
JP3600252B2 (ja) 2004-12-15
BE1005696A3 (fr) 1993-12-21
DE4223284A1 (de) 1993-01-28
FI923320A0 (fi) 1992-07-21
AT408609B (de) 2002-01-25
TW260610B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1995-10-21
CA2074322C (en) 2003-04-08
FR2680109A1 (fr) 1993-02-12
AU651711B2 (en) 1994-07-28
EE03014B1 (et) 1997-08-15
CA2074320A1 (en) 1993-01-23
NL194577B (nl) 2002-04-02
AU2043792A (en) 1993-01-28
GR920100323A (el) 1993-05-24
HRP920229A2 (en) 1996-04-30
IL102590A (en) 1997-07-13
FR2679450B1 (fr) 1995-06-09
IL102591A (en) 1997-06-10
ITBS920093A0 (it) 1992-07-21
IL102591A0 (en) 1993-01-14
SI9200152A (en) 1993-03-31
SI9200152B (sl) 1998-06-30
ATA148992A (de) 1997-06-15
SE9202212L (sv) 1993-01-23
ITBS920092A1 (it) 1994-01-21
DE4223282A1 (de) 1993-01-28
JPH05221855A (ja) 1993-08-31
NL194576B (nl) 2002-04-02
DK176219B1 (da) 2007-02-26
ZA925485B (en) 1993-04-28
GR1001446B (el) 1993-12-30
IE71199B1 (en) 1997-02-12
GB2257909B (en) 1996-01-10
CN1054543C (zh) 2000-07-19
KR930702018A (ko) 1993-09-08
FI923321A0 (fi) 1992-07-21
SE9202213D0 (sv) 1992-07-21
GB2257909A (en) 1993-01-27
NL194576C (nl) 2002-08-05
CA2074322A1 (en) 1993-01-23
HU9301186D0 (en) 1993-07-28
HU218203B (hu) 2000-06-28
BR9205375A (pt) 1994-03-08
CZ287585B6 (cs) 2000-12-13
DK93892D0 (da) 1992-07-21
JP2842736B2 (ja) 1999-01-06
DE4223284C2 (de) 1997-07-31
US5637568A (en) 1997-06-10
ITBS920092A0 (it) 1992-07-21
US5445832A (en) 1995-08-29
IT1259891B (it) 1996-03-28
NL9201310A (nl) 1993-02-16
ES2050070A1 (es) 1994-05-01
DK176218B1 (da) 2007-02-26
SK280612B6 (sk) 2000-05-16
NO922886L (no) 1993-01-25
NO922885L (no) 1993-01-25
NL194577C (nl) 2002-08-05
GR1002548B (el) 1997-01-28
DE9219084U1 (de) 1997-09-25
NO304136B1 (no) 1998-11-02
IE69967B1 (en) 1996-10-16
RU2103994C1 (ru) 1998-02-10
NO922885D0 (no) 1992-07-21
ATA148892A (de) 2001-06-15
GB2257973A (en) 1993-01-27
DK93992A (da) 1993-01-23
ZA925486B (en) 1993-04-28
PT100712B (pt) 1999-07-30
PT100713A (pt) 1993-08-31
CZ66093A3 (en) 1994-01-19
IT1259892B (it) 1996-03-28
NZ243643A (en) 1993-10-26
MX9204268A (es) 1994-03-31
CH683592A5 (fr) 1994-04-15
DK93992D0 (da) 1992-07-21
PT100713B (pt) 1999-07-30
FR2680109B1 (fr) 1994-09-02

Similar Documents

Publication Publication Date Title
ES2050070B1 (es) Procedimiento para la preparacion de una composicion destinada a la liberacion prolongada y controlada de una substancia peptidica.
CO4890855A1 (es) Formulaciones acuosas de peptidos
ES2128329T3 (es) Conjugados de proteina-polietilenglicol.
ATE238813T1 (de) Wirkstoffformulierungen mit verzögerter freisetzung
AR020062A1 (es) Una composicion farmaceutica solida o semisolida para la liberacion sostenida de peptidos
PT1238658E (pt) Administracao controlada de um agente activo que utiliza um sistema implantavel
PE20030400A1 (es) Productos en gel para la axila con componentes de bloque de agua
BR0107942A (pt) Polìmeros de proteìna de liberação lenta
BR0012429A (pt) Fórmulações para il-11
MX9705710A (es) Compuestos con propiedades de liberacion de la hormona del crecimiento.
AR003933A1 (es) Micelas mixtas, composiciones acuosas que las contienen, procedimiento para la obtencion de las micelas mixtas y empleo de las micelas mixtas.
BR0203650A (pt) Estentor de auto-articulação
ATE257014T1 (de) Lichtbilderzeugungskontrastmitteln
MY118151A (en) Pharmaceutical formulations containing voriconazole.
BR9906903A (pt) Composição com liberação sustentada, processos para produzir a mesma, para suprimir a brusca liberação inicial da susbtância bioativa de uma composição com liberação sustentada e para aumentar a eficiência da inclusão da substância bioativa em uma composição com liberação sustentada, produto farmacêutico, agente para prevenir ou tratar câncer prostático, hipertrofia prostática, endometriose, histeromioma, metrofibroma, puberdade precoce, dismenorréia, ou câncer do seio, ou um contraceptivo, e, composto
ES2179207T3 (es) Formulaciones de hierro dextrano.
CY1105647T1 (el) Γαλακτωματα για συστηματα απελευθερωσης in-situ
AR065073A2 (es) Una formulacion medicamentosa de sistema de matriz que tiene liberacion controlada de un compuesto activo
AU7814498A (en) Multivalent (in ovo) avian vaccine
BR9902528A (pt) Sistema implantável e implante destinado à administração subcutânea ou local
NO994431L (no) Ny formulering
ES2169223T3 (es) Substancia anticancerosa que inhibe la metastasis cancerosa.
ES2071509T3 (es) Composiciones desodorantes liquidas.
DE60003943D1 (de) Trimegestone enthaltende pharmazeutische zusammensetzungen
DK0921793T3 (da) Faste, ikke-henflydende formuleringer af natriumvalproat

Legal Events

Date Code Title Description
PC2A Transfer of patent
PC2A Transfer of patent
FD1A Patent lapsed

Effective date: 20070723